Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.3.0.814
Summary of Significant Accounting Policies (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Segment
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Summary of Significant Accounting Policies [Line Items]          
Goodwill and intangible assets $ 2,200,000   $ 2,200,000   $ 1,100,000
Amortization of intangible assets 8,110 $ 2,735 14,011 $ 8,304  
Other revenue, principally transfer of intellectual property 18,350 $ 0 48,552 476  
Total deferred revenue related to other revenues 254,100   254,100   6,700
Accounts receivable, net 189,725   189,725   19,969 [1]
Allowance for doubtful accounts receivable 9,115   9,115   1,906
Equity-based compensation expense for continuing operations     $ 17,765 $ 10,088  
Number of reportable segments | Segment     2    
Release of OPKO's valuation allowance     $ 93,400    
Accrual for uncertain tax positions     $ 2,300    
Pharmaceuticals          
Summary of Significant Accounting Policies [Line Items]          
Number of operating segments | Segment     2    
Diagnostics          
Summary of Significant Accounting Policies [Line Items]          
Number of operating segments | Segment     2    
Minimum          
Summary of Significant Accounting Policies [Line Items]          
Intangible assets, estimated useful lives     3 years    
Useful life     5 years    
Estimate of possible loss     $ 0    
Maximum          
Summary of Significant Accounting Policies [Line Items]          
Intangible assets, estimated useful lives     20 years    
Useful life     10 years    
Estimate of possible loss     $ 50,000    
Medicare and Medicaid          
Summary of Significant Accounting Policies [Line Items]          
Accounts receivable, net $ 22,800   $ 22,800   $ 600
Medicare and Medicaid | Sales Revenue          
Summary of Significant Accounting Policies [Line Items]          
Percentage of revenue 9.00% 5.00%      
Medicare and Medicaid | Accounts Receivable          
Summary of Significant Accounting Policies [Line Items]          
Percentage of revenue     9.00% 0.50%  
Software          
Summary of Significant Accounting Policies [Line Items]          
Useful life     3 years    
Machinery and equipment | Minimum          
Summary of Significant Accounting Policies [Line Items]          
Useful life     5 years    
Machinery and equipment | Maximum          
Summary of Significant Accounting Policies [Line Items]          
Useful life     8 years    
Furniture and fixtures | Minimum          
Summary of Significant Accounting Policies [Line Items]          
Useful life     5 years    
Furniture and fixtures | Maximum          
Summary of Significant Accounting Policies [Line Items]          
Useful life     10 years    
Buildings and improvements | Minimum          
Summary of Significant Accounting Policies [Line Items]          
Useful life     10 years    
Buildings and improvements | Maximum          
Summary of Significant Accounting Policies [Line Items]          
Useful life     40 years    
Collaborative Arrangement, Product | Pfizer          
Summary of Significant Accounting Policies [Line Items]          
Total deferred revenue related to other revenues $ 247,200   $ 247,200    
Revenue from sale of intellectual property $ 17,700   $ 47,800    
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 5. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.